Atreca to Cut About 40% of Workforce

marketwatch
2023/11/15

By Josh Beckerman

Biotechnology company Atreca said it is implementing a further reduction in its workforce of about 40% while maintaining the necessary support to continue exploring potential strategic transactions and business alternatives.

The company cited financial market conditions and the funding needs required to advance antibody-drug conjugate programs into clinical development.

Atreca also reported a third-quarter loss of 92 cents a share, compared with a loss of 60 cents a share a year earlier.

Write to Josh Beckerman at josh.beckerman@wsj.com

 

免责声明:投资有风险,本文并非投资建议,以上内容不应被视为任何金融产品的购买或出售要约、建议或邀请,作者或其他用户的任何相关讨论、评论或帖子也不应被视为此类内容。本文仅供一般参考,不考虑您的个人投资目标、财务状况或需求。TTM对信息的准确性和完整性不承担任何责任或保证,投资者应自行研究并在投资前寻求专业建议。

热议股票

  1. 1
     
     
     
     
  2. 2
     
     
     
     
  3. 3
     
     
     
     
  4. 4
     
     
     
     
  5. 5
     
     
     
     
  6. 6
     
     
     
     
  7. 7
     
     
     
     
  8. 8
     
     
     
     
  9. 9
     
     
     
     
  10. 10